The purpose of the present study was to examine the expression of CD105 among patients with supraglottic laryngeal cancer and to assess the clinical relevance of CD105-assessed MVD. A total of 40 patients with supraglottic squamous cell carcinomas (SCCs) were included in the present study. Surgical specimens were immunostained for CD105 and MVD was calculated at 400x magnification. The rounded mean value of the vessel count in four fields for each case was used as the final MVD value. The mean MVD value assessed by CD105 in considered supraglottic SCCs was 13.5 (SD = 3.97). High MVD was significantly correlated with advanced (III and IV) clinical stage (Mann-Whitney U test P = 0.01) and malignancy recurrence presence/absence (Mann-Whitney U test P = 0.023). Spearman's rank correlation test showed significant correlation between high CD105-assessed MVD and pN+ category (rho = 0.337, P = 0.033), advanced Stage (III and IV) (rho = 0.402, P = 0.01) and developed locoregional recurrence (rho = 0.395, P = 0.012). The logistic regression showed that a high CD105+ MVD was the only independent marker of tumor recurrence (P = 0.029; odds ratio, 6.64; 95% CI, 1.218-36.152). The average MVD was significantly higher in patients with advanced TNM stage and in patients with locoregional recurrence of disease, suggesting that angiogenesis is closely related with clinical aggressiveness of tumor. CD105-assessed MVD in supraglottic laryngeal SSCs may identify patients at risk of recurrence of disease.

The present results suggest that MVD evaluation with CD105 is a promising prognostic factor for the outcome of patients with laryngeal SCC. CD105-assessed MVD could help to identify patients with more aggressive disease and increased risk of developing malignancy recurrence after treatment.

No abstract

Triple negative breast cancer (TNBC) account for 12% to 17% of all breast cancers. It is a heterogeneous group of tumors associated with aggressive clinical course. Insulin-like growth factor II mRNA binding protein 3 (IMP3) belongs to a family of insulin-like growth factor type II (IGF2), which plays a key role in the transmission and stabilization of mRNA, cell growth, and migration during embryogenesis. Increased expression of IMP3 is associated with aggressive behavior of different tumor types, advanced clinical stage, distant metastasis, and shorter overall survival (OS). The study included 118 patients with breast carcinoma diagnosed as TNBC and immunohistochemical staining for estrogen receptors (ER), progesterone receptors (PR), epidermal growth factor receptor 2 (HER2/neu), Ki-67, and IMP3 was performed. Correlations between categorical variables were studied using the chi-square and the Mann–Whitney U test. For survival analysis, the Kaplan–Meier method, log-rank test and the Cox proportional hazard regression model were used. Positive expression of IMP3 protein was present in 35.6% of TNBC. The presence of basal morphology was observed in 46.6% of TNBC. Positive IMP3 expression was connected with larger size of tumor, higher clinical stage, and basal morphology (P = .039, P = .034, P < .001). Disease-free survival and OS were significantly shorter in IMP3 positive TNBC. According to results of our study IMP3 expression can be used as negative prognostic factor for triple negative breast carcinomas. Targeting IMP3 molecule could be an effective approach to the management of a triple negative breast cancer with new immunological therapies, which does not yet exist for this group of tumors.

BACKGROUND Leiomyosarcoma (LMS) of the thyroid gland is a rarely presented tumor that offers poor prognosis. To the best of the authors’ knowledge, there currently exist only 28 known cases described in the literature (limited to English). CASE SUMMARY Herein a case is reported of a 60-year-old female patient who had an LMS of the thyroid, which was accompanied by periodic dysphonia and breathing disorder as well as the feeling of pressure in the chest and neck. At the time the disease was diagnosed, no metastases were detected. Prior to the diagnosis, the patient experienced a uterine adenocarcinoma that had been treated by surgical procedure and radiotherapy. For the LMS, a total thyroidectomy was performed, followed by radiotherapy. Since metastases were also discovered in the lungs, sternum, and femur, chemotherapy was administered as well. Immunohistochemically, the tumor cells in the thyroid indicated positively for alpha smooth muscle actin, calponin, and H-caldesmon, but were negative for CD34, p63, estrogen receptor, progesterone receptor, and Epstein-Barr virus. CONCLUSION Although the etiology of the LMS is as of yet unknown, prior malignancy and radiation should be considered as risk factors.